Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Adjuvant Chemotherapy. Found 61 abstracts

no pagination
Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MA, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol. 2020 Apr;203(4):684-9.
Hamy AS, Tury S, Wang X, Gao J, Pierga JY, Giacchetti S, Brain E, Pistilli B, Marty M, Espie M, Benchimol G, Laas E, Lae M, Asselain B, Aouchiche B, Edelman M, Reyal F. Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. J Clin Oncol. 2019 Mar 10;37(8):624-35.   PMCID: PMC6804843
Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K. Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. European urology focus. 2019 Mar;5(2):242-9.   PMCID: PMC5712487
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD. Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. European urology focus. 2018 Dec;4(6):937-45.   PMCID: PMC5626651
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol. 2017 Sep;3(9):1249-52.   PMCID: PMC5591751
Chan JK, Java JJ, Fuh K, Monk BJ, Kapp DS, Herzog T, Bell J, Young R. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials. Gynecol Oncol. 2016 Dec;143(3):490-5.   PMCID: PMC5728987
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Kelly Marcom P, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R. Invasive breast cancer version 1.2016. JNCCN Journal of the National Comprehensive Cancer Network. 2016 Mar;14(3):324-54.
Guttmann DM, Li H, Sevak P, Grover S, Jacobson G, Feldman A, Rubin S, Chu C, Bhatia S, Elshaikh MA, Lin LL. The Impact of Adjuvant Therapy on Survival and Recurrence Patterns in Women With Early-Stage Uterine Carcinosarcoma: A Multi-institutional Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2016 Jan;26(1):141-8.
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2016 May 14;387(10032):2008-16.   PMCID: PMC4878938
Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, Griggs JJ, Levenback CF, Burger RA, Mantia-Smaldone G, Matulonis UA, Niland JC, O'Malley DM, Wright AA. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 Sep 06;34(32):3854-63.   PMCID: PMC5477982
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow J, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian L, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. The New England journal of medicine. 2015 Mar 05;372(10):923-32.   PMCID: 4405231
Porpiglia AS, Sigurdson ER. Surgical Options in the Treatment of Lower Gastrointestinal Tract Cancers. Current treatment options in oncology. 2015 Sep;16(9):46.
Vijayvergia N, Shah PC, Denlinger CS. Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward. J Natl Compr Canc Netw. 2015 Sep;13(9):1151-61.
Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology. 2014 Sep;32(27):2959-66.   PMCID: 4162494
McCleary NJ, Dotan E, Browner I. Refining the chemotherapy approach for older patients with colon cancer. J Clin Oncol. 2014 Aug 20;32(24):2570-80.
Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, Mehrazin R, Boorjian SA, Kelly WK, Uzzo RG, Hudes GR. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol. 2014 Jun 20;32(18):1895-901.   PMCID: PMC4050203
Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol Oncol. 2014 Aug;32(6):826-32.   PMCID: PMC4687398
Canter D, Long C, Kutikov A, Plimack E, Saad I, Oblaczynski M, Zhu F, Viterbo R, Chen DY, Uzzo RG, Greenberg RE, Boorjian SA. Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU international. 2011 Jan;107(1):58-62.
Canter D, Viterbo R, Kutikov A, Wong YN, Plimack E, Zhu F, Oblaczynski M, Berberian R, Chen DY, Greenberg RE, Uzzo RG, Boorjian SA. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology. 2011 Jan;77(1):160-5.   PMCID: publisher will deposit
Langer CJ. Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment?. Drugs Aging. 2008 Jan;25(3):209-18.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Adjuvant Chemotherapy

Adjuvant Chemotherapy pathology Female Middle Aged drug therapy Aged therapeutic use surgery Neoplasm Staging methods Antineoplastic Combined Chemotherapy Protocols Male Disease-Free Survival mortality Adult therapy Prognosis Urinary Bladder Neoplasms Neoadjuvant Therapy adverse effects Survival Rate 80 and over Aged Antineoplastic Agents Neoplasm Invasiveness administration & dosage Randomized Controlled Trials as Topic Cystectomy Treatment Outcome Combined Modality Therapy Local Neoplasm Recurrence Transitional Cell Carcinoma Kidney Neoplasms Tumor Biomarkers Follow-Up Studies Lymph Node Excision drug effects Renal Cell Carcinoma Phase III Clinical Trials as Topic Adjuvant Radiotherapy Retrospective Studies Cisplatin Breast Neoplasms Kaplan-Meier Estimate Proportional Hazards Models epidemiology analogs & derivatives Time Factors Niacinamide secondary Fatigue Kidney Multivariate Analysis Double-Blind Method Progression-Free Survival Phenylurea Compounds Urothelial carcinoma Cytoreduction Surgical Procedures Colonic Neoplasms Sorafenib Sunitinib Risk Factors Carboplatin Prospective Studies Indoles Pyrroles chemically induced Non-Small-Cell Lung Carcinoma Ovarian Neoplasms Lung Neoplasms Neoplasm Metastasis Drug Administration Schedule analysis Lymph Nodes Age Factors Protective Agents dosage Pain Young Adult Survivors Urothelium Premenopause Paclitaxel Celecoxib etiology Robot-assisted surgery Rectal Neoplasms Micropapillary physiopathology local Oral Administration Adenocarcinoma Radiotherapy Triple Negative Breast Neoplasms Survey Hysterectomy statistics & numerical data Cell Survival Postchemotherapy lymphadenectomy Smooth Muscle Perioperative Care Adolescent Methotrexate Recombinant Proteins Survival Predictive Value of Tests Fertility Preservation Muscle-invasive disease United States Mammaplasty Margins of Excision Gastrointestinal Endoscopy carcinoma Parenteral Infusions Gonadotropin-Releasing Hormone Estrogen Receptors Vinblastine Nephrectomy Quality of Life enzymology Goserelin Squamous Cell Carcinoma Motor Activity Epidemiologic Methods Patient Selection Tumor-Infiltrating Lymphocytes chemistry Doxorubicin Glandular and Epithelial Neoplasms Bladder cancer Lymphatic Metastasis Second Primary Neoplasms Phase II Clinical Trials as Topic Medical Oncology Multicenter Studies as Topic Risk Assessment Smoking Cyclophosphamide Logistic Models Early stage ovarian cancer Pelvis prevention & control Urinary Diversion Cystic Neoplasms-Mucinous-and Serous neoplasm recurrence Tumor Cell Line Retroperitoneal Space Fecal Incontinence Brachytherapy Polyethylene Glycols Pregnancy
Last updated on Saturday, August 15, 2020